Barinthus Biotherapeutics plc.

BRNS Nasdaq SEC CIK 1828185
Follow Barinthus Biotherapeutics plc. Weekly email: filings, results, news

Financials

Reported figures only · latest: Q2 2026 USD · US GAAP
Net income −$10.6M +49.9% vs same quarter last year
EPS, diluted −$0.26 +50% vs same quarter last year
Operating cash flow −$8.1M +55.3% vs same quarter last year
Operating income −$11M +52.8% vs same quarter last year
Revenue by quarter
$15M
$0
$0
$0
Q3 24 Q4 24 Q3 25 Q4 25

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
  • Revenue
  • Net income
−$100M−$50M$0$50MFY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$0−$66.4M
FY24$15M−$61.1M
FY23$802K−$73.3M
FY22$44.7M$5.3M
FY21$268K−$50.9M
FY20$4.8M−$17.7M
FY19--
MarginsShare of revenue
  • Operating margin
  • Net margin
−20000%−15000%−10000%−5000%0%5000%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearOperating marginNet margin
FY25--
FY24−454.1%−408%
FY23−10463.1%−9145.5%
FY22−9%11.9%
FY21−16873.5%−18979.5%
FY20−415.8%−367.3%
FY19--
Free cash flowOperating cash flow minus capital expenditure
−$60M−$40M−$20M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$48M
FY24−$29.8M
FY23−$56.3M
FY22−$20.6M
FY21−$33.7M
FY20−$11.3M
FY19-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Barinthus Biotherapeutics plc.
  • Healthcare median
−20000%−15000%−10000%−5000%0%5000%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearBarinthus Biotherapeutics plc.Healthcare median
FY25-−66.4%
FY24−408%−87%
FY23−9145.5%−128.5%
FY2211.9%−143.6%
FY21−18979.5%−137.7%
FY20−367.3%−134.3%
FY19-−125.9%

News

No stories filed under Barinthus Biotherapeutics plc. yet - coverage appears here as the news feed clusters it.